PDCD1 and neoplasm: Additionally, preliminary data from a phase II clinical trial with IMM01 demonstrated a robust anti-tumor effectiveness with a well-tolerated safety profile in classical Hodgkin lymphoma patients who had failed prior anti-PD-1 therapy (59).